Market Place
Sourcing Support
Vincerx Pharma to Merge with Oqory, Inc.
27 Dec 2024 //
GLOBENEWSWIRE
Vincerx Pharma Implements Cost Controls for Ph 1 VIP943 Study
04 Dec 2024 //
GLOBENEWSWIRE
Vincerx Pharma Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
Vincerx Pharma Reports Q1 2024 Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
Vincerx Prices Underwritten Public Offering of Stock & Warrants
26 Apr 2024 //
GLOBENEWSWIRE
Vincerx Presents Ph 1 Data for VIP236 at the AACR Annual Meeting 2024
08 Apr 2024 //
GLOBENEWSWIRE
Vincerx to Host Event Reviewing Ph 1 VIP236 Data Presented at the AACR Meeting
01 Apr 2024 //
GLOBENEWSWIRE
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 2024 //
GLOBENEWSWIRE
Vincerx to Present Three Posters at the American Association
05 Mar 2024 //
PRESS RELEASE
Vincerx Announces Compelling Efficacy of Enitociclib with Venetoclax
07 Jan 2024 //
GLOBENEWSWIRE
Vincerx Pharma To Present Three Posters at ASH 2023 in December
02 Nov 2023 //
GLOBENEWSWIRE
Vincerx `pacing investment` in ADC to free cash for lead assets
08 Aug 2023 //
FIERCE BIOTECH
Vincerx Pharma Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Vincerx Pharma Presents Preclinical Data on VIP924, a (ADC)
19 Apr 2023 //
GLOBENEWSWIRE
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class(SMDC
17 Apr 2023 //
GLOBENEWSWIRE
Vincerx Presents Preclinical Data on Novel Small Molecule Drug Conjugates AACR
17 Apr 2023 //
GLOBENEWSWIRE
Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference
06 Feb 2023 //
GLOBENEWSWIRE
Vincerx Announces FDA Safe to Proceed Letter for IND for ?V?3 SMDC VIP236
13 Dec 2022 //
GLOBENEWSWIRE
Vincerx Pharma Provides American Society Hematology Annual Meeting 2022 Poster
12 Dec 2022 //
GLOBENEWSWIRE
Vincerx Pharma Presents Preclinical Data on VIP943 at ASH
11 Dec 2022 //
GLOBENEWSWIRE
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th (ASH)
03 Nov 2022 //
GLOBENEWSWIRE
Vincerx Pharma Reports Q2 2022 Rusult and Provides a Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
Vincerx Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152
10 Jun 2022 //
GLOBENEWSWIRE
Vincerx Pharma Provides Key Strategic Update
06 Jun 2022 //
GLOBENEWSWIRE
Vincerx Pharma Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Vincerx Pharma Presents Clinical Data on PTEFb/CDK9 Inhibitor VIP152
08 Apr 2022 //
GLOBENEWSWIRE
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Vincerx Pharma says Poster Presentation at the AACR
08 Mar 2022 //
GLOBENEWSWIRE
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Conference
09 Feb 2022 //
GLOBENEWSWIRE
Vincerx Pharma Publishes PC Data Demonstrating Therapeutic Potential of VIP236
03 Feb 2022 //
GLOBENEWSWIRE
Vincerx Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152
17 Dec 2021 //
GLOBENEWSWIRE
Vincerx Receives Orphan Drug Designation from European Commission for VIP152
07 Dec 2021 //
GLOBENEWSWIRE
Vincerx Pharma Reports Q3 2021 Financial Results and Provides a Corporate Update
12 Nov 2021 //
GLOBENEWSWIRE
Vincerx to Present at the ASH 2021
04 Nov 2021 //
GLOBENEWSWIRE
